The data of Sinopharm Xinguan vaccine was released for the first time, and who revealed the details; Nature reviews five vaccines approved in China

“Click ­čĹć´╝î Knowledge is power

.

Getourfreedailynewsletter   Knowledge is power

.

You can subscribe to the free “Xinguan daily” separately

.

Key words: covid-19; Vaccines; Chinese medicine; China; For the first time, the details of the protective capacity data of the inactivated virus vaccine bbibp CorV of nature Sinopharm group were released

.

Sinopharm reported the data of vaccine bbibp CorV from Beijing Institute of biological products to the World Health Organization (who)

.

A total of 45000 people were enrolled in phase III trials in the United Arab Emirates, Bahrain, Egypt and Jordan, according to the report

.

The vaccination group and placebo group were 13765 people each, and were followed up for 112 days

.

There were 21 cases in the vaccination group and 95 cases in the placebo group

.

The protective effect was 78.1% (95% CI 64.9-86.3%)

.

The WHO evaluation report has been published, and it is likely that the vaccine will be included in the WHO emergency use authorization in the next few weeks, so as to further provide vaccines to other countries in the world through the who’s covid-19 global access to vaccines (covax) program

.

At the same time, corona VAC, a vaccine from China’s Kexing biology, was evaluated

.

Links to the original documents of the two reports can be found in the references at the end of this paper

.

According to the statement of quality of evidence of who on the data of Sinopharm group, the bbibp-corv of Sinopharm group has high credibility of evidence and medium credibility of safety (serious adverse events) for adults aged 18-59 years without risk factors; For the elderly and people with risk factors, the evidence credibility of protection and safety is very low

.

It should be noted that the credibility of evidence is very low, which does not mean that it is invalid; But because the number of subjects in the clinical trial of that observation group was too small, the conclusion was not reliable

.

On May 4, 2021, Nature magazine specially published an overview of 5 (3 categories) vaccines approved in China by Smriti mallapaty

.

Vaccines of Sinopharm and Kexing are the main components of vaccination in China

.

By 3pm on May 4, statistics showed that the mainland of China had received 28000 doses of vaccine, accounting for 23% of all vaccinations in the world; In the last week, China received 7.2 million doses of vaccine a day, more than three times as many as the United States, which ranked second´╝ł Photo source: Peng Bo) in addition to China, 45 other countries and regions have used China’s inactivated virus vaccine to prevent covid-19

.

The vaccine approved by who through emergency use authorization can be purchased by covax and supplied to economically underdeveloped countries

.

Therefore, the requirements of covax for vaccines mainly include: large supply, easy transportation, low price and who approval

.

So far, covax has signed a supply plan of 2 billion doses of vaccines, mainly adenovirus vaccines produced by AstraZeneca and Johnson & Johnson; One billion of them are AstraZeneca vaccines produced in India

.

However, due to the recent cowid-19 crisis in India, the export vaccine program has been suspended

.

So only about 50 million doses of vaccine have been delivered

.

In this case, Chinese vaccines may be critical for the supply of covax vaccines

.

China is the first country to develop covid-19 vaccine

.

It has developed in different categories, such as inactivated virus vaccine, adenovirus vector vaccine, recombinant protein vaccine and mRNA vaccine

.

However, there is an important problem in these R & D projects: the results of clinical trials have not been published or even made public

.

Open and transparent data is not only the basic requirement of clinical research, but also the basic condition for approval

.

Relatively speaking, China Kexing biology has done the best in data disclosure

.

See: the results of the first key phase 3 clinical trial of Chinese vaccine published: Kexing vaccine, 12000 + participated in Nature magazine

.

The summary results of five vaccines in China are as follows: the data shows that the estimated production capacity of inactivated virus vaccine companies in China alone in 2021 will reach 4 billion doses, which is not only enough for domestic use, but also can provide more than 1 billion doses of vaccine to other countries

.

The WHO assessment provides a more detailed picture of the protection of inactivated vaccines in both countries

.

The overall protection of the vaccine against symptomatic covid-19 was 78.1%, and the protection against hospitalization was 78.7%

.

However, only adults aged 18-59 years without risk factors were more reliable´╝ł Photo source: who report) the protective effect of Kexing vaccine on prevention of symptomatic covid-19 was 67%, on prevention of hospitalization was 85%, and on prevention of death was 80%

.

The conclusion is reliable for adults aged 18-59 without risk factors; For the elderly or adults with risk factors, the assessment is reliable´╝ł Photo source: who report) (photo source: who report) editor’s note: the data released by who provide us with more data about Sinopharm group and Kexing inactivated vaccine

.

The protective effect of bbibp CorV was 78.1%

.

This conclusion is highly reliable only in people aged 18-59 years without risk factors

.

The protective effect of coronavac was 67%

.

This conclusion is highly reliable in 18-59 years old people without risk factors; For the elderly or adults with risk factors, the reliability was verified

.

At present, who has approved four vaccines through emergency use authorization, including AstraZeneca’s adenovirus vector vaccine in the United Kingdom, Pfizer / biontech’s mRNA vaccine in the United States, Johnson & Johnson’s adenovirus vector vaccine in the United States and Moderna’s mRNA vaccine in the United States

.

If Sinopharm and Kexing vaccines are approved by who, they will be the fifth approved vaccine and the first inactivated virus vaccine

.

This is a necessary step for China to provide vaccine to other countries through who

.

We often receive messages from the background

.

What is the data we always mention? Whether it’s the last protective number

.

As for data, Wikipedia says very clearly: data are information of information, of numerical, that are collected through observation

.

Inamore technical sense, data are ease of values of qualitative variables as a body of information persons objects

.

From a more professional point of view, data is a set of numerical values composed of qualitative or quantitative parameters of one or more individuals / things

.

Therefore, the data is not only 78.1%, but also the detailed parameters behind it; Only in this way can we judge whether the number is reliable

.

Open and transparent data is the most basic requirement for clinical trials and vaccine / drug approval.

.